Abstract: Substances of polypeptide nature are obtainable by extraction with HClO.sub.4 and 3M KCl from animal tissue homogenates. The substances have the characteristics of (a) molecular weights ranging from 10,000 to 50,000 daltons (by polyacrylamide gel electrophoresis); (b) are capable of inducing the formation of antibodies which specifically bind in vivo or in vitro antigens which are present in human tumoral cells, when administered to different animal species; (c) are capable of decreasing or inhibiting pain; (d) induce an effect of cell lysis; and (e) inhibit or slow tumor growth, when administered to humans affected by malignant tumors of different kinds.

Abstract: The present invention provides novel fusion proteins comprising cyclins and CDKs. A preferred embodiment of the invention provides fusion proteins comprising human cyclin D1 and human CDK4. The fusion proteins of the invention optionally contain modifications, which facilitate their purification. Addition of histidine residues to selected constructs allows purification via immobilized metal affinity chromatography. Antigenic determinants allowing monoclonal antibody-based affinity chromatography purification are provided in selected embodiments of the invention. Protease cleavage sites are incorporated in selected constructs to allow cleavage of the regions incorporated in the cyclin-CDK fusion proteins for purification. Additional modifications which facilitate purification include strepavadin binding domains and antigenic determinants for antibody affinity chromatography.

Abstract: The present invention provides isolated peptides of Lol p V, a major protein allergen of the species Lolium perenne. Therapeutic peptides within the scope of the invention comprise at least one T cell epitope, or preferably at least two T cell epitopes of a protein allergen of Lol p V. Diagnostic peptides within the scope of the invention bind IgE. The invention also provides modified peptides having similar or enhanced therapeutic properties as the corresponding, naturally-occurring allergen or portion thereof, but having reduced side effects. The invention further provides nucleic acid sequences coding for peptides of the invention. Methods of treatment or diagnosis of sensitivity to Lol p V or an allergen immunologically related to Lol p V in an individual. Therapeutic compositions comprising one or more peptides of the invention are also provided.

Abstract: Human hematopoietic stem cells are identified according to expression of specific cell surface markers. Substantially homogenous stem cell compositions are obtained by selective isolation of cells free of markers associated with differentiated cells, while displaying epitopic characteristics associated with the stem cells. The stem cells may then be maintained by regeneration in an appropriate growth medium. Means are provided for assaying for the stem cells as to their capability for producing members of each of the hematopoietic lineages.